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A B S T R A C T
Background
Promoter hypermethylation coupled with loss of heterozygosity at the same locus results in
loss of gene function in many tumor cells. The ‘‘rules’’ governing which genes are methylated
during the pathogenesis of individual cancers, how specific methylation profiles are initially
established, or what determines tumor type-specific methylation are unknown. However, DNA
methylation markers that are highly specific and sensitive for common tumors would be useful
for the early detection of cancer, and those required for the malignant phenotype would
identify pathways important as therapeutic targets.
Methods and Findings
In an effort to identify newcancer-specificmethylationmarkers, we employed a high-throughput
global expression profiling approach in lung cancer cells. We identified 132 genes that have 59 CpG
islands, are induced from undetectable levels by 5-aza-29-deoxycytidine in multiple non-small cell
lung cancer cell lines, and are expressed in immortalized human bronchial epithelial cells. As
expected, thesegeneswerealsoexpressed innormal lung,butoftennot in companionprimary lung
cancers. Methylation analysis of a subset (45/132) of these promoter regions in primary lung cancer
(n¼20) and adjacent nonmalignant tissue (n¼20) showed that 31 genes had acquiredmethylation
in the tumors, butdidnot showmethylation innormal lungor peripheral blood cells.We studied the
eight most frequently and specifically methylated genes from our lung cancer dataset in breast
cancer (n ¼ 37), colon cancer (n ¼ 24), and prostate cancer (n ¼ 24) along with counterpart
nonmalignant tissues.We found that seven lociwere frequentlymethylated inbothbreast and lung
cancers, with four showing extensive methylation in all four epithelial tumors.
Conclusions
By using a systematic biological screen we identified multiple genes that are methylated with
high penetrance in primary lung, breast, colon, and prostate cancers. The cross-tumor
methylation pattern we observed for these novel markers suggests that we have identified a
partial promoter hypermethylation signature for these common malignancies. These data
suggest that while tumors in different tissues vary substantially with respect to gene
expression, there may be commonalities in their promoter methylation profiles that represent
targets for early detection screening or therapeutic intervention.
The Editors’ Summary of this article follows the references.
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Introduction
Tumor-acquired alterations in DNA methylation include
both genome-wide hypomethylation and locus-speciﬁc hyper-
methylation. Genomic hypomethylation occurs early in
cellular transformation and affects both genome stability
and imprinted gene expression [1–3]. Promoter hypermethy-
lation often coincides with loss of heterozygosity at the same
locus, which can result in the loss of function of the gene in
tumor cells. These genetic and epigenetic changes often
occur at tumor suppressor gene loci, and are hypothesized to
participate in cancer development [4].
While genomic methylation patterns are clearly deranged
in cancer cells, the DNA methyltransferases themselves are
rarely if ever mutated or aberrantly expressed [5]. The ‘‘rules’’
governing which genes are methylated during the patho-
genesis of individual cancers, as well as the timing of their
methylation and silencing (e.g., during preneoplasia or in
metastatic progression) are unknown, and it is not yet clear
how speciﬁc methylation patterns are initially established in
tumor cells [6,7]. However, aberrant promoter hypermethy-
lation is common to most tumors, and in many cases, appears
to have tumor-type speciﬁcity [8]. A few genes, such as the
cyclin-dependent kinase inhibitor (p16) and the tumor
suppressor gene ras association domain family protein 1A
(RASSF1A) are methylated across many tumor types, but they
appear to be exceptions. Identiﬁcation of more genes of this
type would represent a common promoter hypermethylation
proﬁle for multiple carcinomas [9–12].
In the present study, we employ gene expression proﬁling
of lung cancer cells and immortalized human bronchial
epithelial cells (HBECs) and contrast their expression
phenotype before and after 5-aza-29-deoxycytidine (5-aza)
treatment to identify genes subject to frequent promoter
hypermethylation in human cancers. Since CpG island
methylation is readily detectable in tissues and ﬂuids, the
identiﬁcation of a promoter hypermethylation gene set that
is common to multiple malignancies—with high frequency
and speciﬁcity for tumors compared to normal tissues—
would have important implications for patient screening,
diagnosis, and therapeutic intervention [12,13].
Methods
Cell Lines and 5-Aza Treatment
With the exception of A549, HCT116, SKBR3, ZR-75–1, and
MCF7, which were purchased from the American Type
Culture Collection (http://www.atcc.org), all tumor cell lines
were established by us and are deposited at the ATCC or are
available upon request [14,15]. Immortalized HBECs were
established by us [16,17].
All cancer cell lines were grown in RPMI-1640 medium
(Life Technologies [http://www.invitrogen.com]) supple-
mented with 10% fetal bovine serum. In the present study,
unless otherwise indicated, HBECs ectopically express mur-
ine cdk4 and hTERT. HBEC lines were grown in KSFM
medium supplemented with bovine pituitary extract and
recombinant human epidermal growth factor (Gibco [http://
www.invitrogen.com]). All cell lines were grown in a humidi-
ﬁed atmosphere with 5% CO2, at 37 8C. A 50 mM stock
solution of 5-aza (Sigma [http://www.sigmaaldrich.com]) was
prepared in DMSO and kept at 80 8C until used. Working
dilutions were prepared from stock aliquots using DMSO
prior to each treatment. Cell lines were incubated in culture
medium with 100 nM or 1 lM 5-aza for 6 d, with medium
changes on days 1, 3, and 5. For H526, which is nonadherent,
cells were agitated with a 200 ll pipette tip in medium
containing 5-aza on days 1, 3, and 5. Cells were harvested and
total RNA extracted on day 6 using Trizol (Invitrogen).
Primary Tumors
DNA from resected primary NSCLCs and corresponding
normal lung tissue was extracted as previously described [18].
A total of 20 primary lung tumor samples and corresponding
nonmalignant lung were randomly selected from a larger
panel (n¼ 107) obtained from NSCLC patients who had been
treated with curative resectional surgery in The Prince
Charles Hospital (Brisbane, Australia) between June 1990
and March 1993. This cohort of patients has been investigated
previously for various genetic abnormalities and includes 76
males and 31 females (age range 28–81 y; mean age at
diagnosis, 61 y) [18–23]. Of these patients, 61 had stage I
disease, 21 had stage II disease, 24 had stage IIIA disease, and
one had stage IIIB disease. Histological subtypes included 45
adenocarcinomas, 43 squamous cell carcinomas, 11 adenos-
quamous carcinomas, four large-cell carcinomas, three
atypical carcinoids, and one typical carcinoid. Ninety-eight
patients were smokers (mean pack-years, 31), and the rest of
patients were never smokers or nonsmokers. Five-year
survival data were available on most patients.
Breast tumor DNA was obtained from patients diagnosed
with stage IIB or later breast cancer. DNA samples from the
University of North Carolina (UNC), the University of
Chicago, and Thomas Jefferson University were prepared as
previously described [24]. All samples were collected with
internal review board approval. Breast tissue sample collec-
tion from the University of Texas Southwestern Medical
Center at Dallas (Dallas, Texas, United States) was approved
by the Institutional Review Board at UT Southwestern
Medical Center, and written informed consent was docu-
mented for each participant. Random periareolar ﬁne needle
aspiration (FNA) was performed as previously described
except that the FNA samples were ﬁxed in Preservcyt (Cytyc
[http://www.cycyc.com]) [25]. DNA was extracted using the
Puregene kit (Gentra Systems [http://www.gentra.com]).
Benign and malignant prostate and colon DNAs were
obtained through the UT Southwestern Tissue Resource
(UTSTR) overseen by the University of Texas Southwestern
Medical Center Institutional Review Board. Tissues were
retrieved from the operating room and samples were snap
frozen in liquid nitrogen within 30 min off of blood supply.
The samples were stored at80 8C until the DNA was isolated
using the Qiagen DNA Isolation Kit (#51306 [http://www.
qiagen.com]). The ﬁnal DNA product was stored in TE buffer
at80 8C until retrieved for sodium bisulﬁte modiﬁcation. All
DNAs in this group of samples were obtained from patients
with stage II or III malignancies.
Sodium Bisulfite Treatment, Methylation-Specific PCR, and
Sodium Bisulfite Sequencing
Sodium bisulﬁte treatment for the UT Southwestern
Medical Center breast FNAs was performed as previously
described, using yeast tRNA as a carrier [26]. Sodium bisulﬁte
modiﬁcation of genomic DNA for the remaining samples and
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methylation-speciﬁc PCR were performed as reported by
Herman et al. with some modiﬁcation to increase sample
throughput [27]. We modiﬁed the protocol to work in 96-well
format as follows: 2 lg of genomic DNA was subjected to
sodium bisulﬁte treatment as before except that samples were
incubated in deep-well (1 ml) 96-well plates using a silicon
seal (Nunc [http://www.nuncbrand.com]), and reagent con-
centrations were modiﬁed to allow the use of a repeat
pipettor (Eppendorf [http://www.eppendorf.com]). An equal
volume of membrane-binding solution (Promega [http://www.
promega.com]) or 4 M guanidine isothiocyanate (Sigma) was
added to the bisulﬁte reaction after 16 h at 50 8C. The
mixture from each well was transferred into the same well on
a binding plate held in a 96-well vacuum manifold, and
evacuated. Bound DNA was washed three times with 80%
isopropanol, then desulfonated in situ with 100 ll of 0.2 N
NaOH for 10 min at room temperature. 100 ll of either
membrane-binding solution or 4 M guanidine isothiocyanate
was added, then evacuated. The desulfonated, bisulﬁte DNA
was washed two more times in 80% isopropanol, and kept
under vacuum for 4 min after the last wash to dry the
membrane. DNA was eluted into a collection plate with 100 ll
of warm (;65 8C), nuclease-free water and further diluted to
250 ll before analysis.
Methylation-speciﬁc PCR primers were designed in part by
using MethPrimer [28], however substantial modiﬁcation was
necessary in most cases. Of the 132 gene 5-aza induction
panel, 45 were selected for methylation analysis because this
number enabled accommodation to a 96-well plate format
including two control sequences (TKTL1 and GAPDH; total 94
primer sets), and two blank wells for negative controls. Each
gene was selected at random from the original 132, and
primers were designed using the following criteria: methyl-
ation-speciﬁc PCR (MSP) primers targeted a region within
250 bp of the annotated transcription start site, where
possible (UCSC Genome Browser [http://genome.ucsc.edu]
and RefSeq [http://www.ncbi.nlm.nih.gov/RefSeq]), contained
three or more CpG sites per primer (most contained four or
more), had a 39-proximal CpG site, and had a predicted
annealing temperature of 55 8C or above. If it was not
possible to design primers using these criteria, the next gene
was selected until a total of 45 was reached. Primers were
purchased from Integrated DNA Technologies (http://www.
idtdna.com) in 96-well format and diluted to 1 lM. Mixed
primers (2 ll each) were added to the corresponding well on
prealiquoted 96-well PCR plates (Invitrogen), and 2 ll of
diluted bisulﬁte DNA was added to each well.
PCR conditions and primer sequences may be found in
Protocol S1.
PCR products were resolved by electrophoresis using 3%
(3:1) agarose in TBE and ethidium bromide. Gels were
visualized using a Kodak (http://www.kodak.com) CCD camera
and images were collated using Adobe Photoshop CS2
(http:www.adobe.com). Several control gels were run using
different combinations of bisulﬁte DNA, agarose, and
running buffers to ensure that the resolving power of the
gel was sufﬁcient to identify the appropriately sized bands
from primer dimers, which did appear in some cases when no
amplicon was present. We were unable to differentiate bands
from background for amplicons that were smaller than 90 bp
using our ﬁnal conditions, which precluded use of GAPDH as
a control. An optically visible band of the appropriate size
was called positive for each primer pair.
Sodium bisulﬁte sequencing was performed using TA
cloning (Invitrogen) as described previously [29]. Sequencing
data were compiled and analyzed using BiQ Analyzer
software, and rendered using a Visual Basic macro in Excel
[30].
Quantitative RT-PCR
Expression of LOX, NRCAM, BNC1, CCNA1, MAF, ALD-
H1A3, CTSZ, IRX4, MSX1, KLF11, SERPINB5, TKTL1, GAPDH,
r18s, and CDKN2A was analyzed by quantitative real-time RT-
PCR. Primers and probes were purchased from Applied
Biosystems assay-on-demand, with the exception of p16,
which was an assay-by-design (Hs00923893_m1) (http://
www.appliedbiosystems.com). All samples were run on the
Chromo 4 Real Time Detector (MJ Research [http://www.
bio-rad.com]) twice, each time in duplicate. We averaged
expression of GAPDH and r18s as internal reference genes to
normalize input cDNA. Quantitative real-time reverse-tran-
scriptase-PCR (QPCR) was performed in a reaction volume of
20 ll including 1 ll of cDNA. We used the comparative Ct
method to compute relative expression values.
RNA Quality and Microarray Analysis
RNA from primary lung cancers were obtained as part of
collaborations with William Gerald at Memorial Sloan-
Kettering Cancer Center (New York dataset) and Chi-Leung
Lam and Maria Wong at the University of Hong Kong. All
samples were collected with appropriate consent and internal
review board approval. Cell line RNA was extracted from cell
lines maintained in the Minna laboratory at UT Southwestern
Medical Center at Dallas as described above.
The quality of total RNA for all samples was analyzed by
formaldehyde gel and/or by capillary electrophoresis on the
Experion System (Bio-Rad). Total RNA was labeled and
ampliﬁed by our genomics core facility, according to manu-
facturer’s instructions (Affymetrix [http://www.affymetrix.
com]). cRNA was reanalyzed after labeling to ensure optimal
ampliﬁcation for most of the samples.
cRNA was hybridized to U133 Plus 2.0 (;47,000 transcripts)
or U133A (;18,400 transcripts) (Affymetrix), and scanned by
our microarray core facility (http://microarray.swmed.edu).
Expression analysis of microarray data was performed using
several algorithms: Robust Multichip Averaging (RMA) [31,32],
Microarray Analysis Suite 5.0 (Affymetrix), MATRIX 1.29 (an
array analysis program written by GL [unpublished data]; see
below), NIH-DAVID [33], Cluster, and TreeView [34].
After scanning, arrays were checked for quality using
GCOS (Gene Chip Operating Software) from Affymetrix and
then normalized using either RMA or MATRIX 1.29. For log
ratio calculations using MAS5 normalization (MATRIX 1.29),
the only requirement was that the numerator be present
(Affymetrix p-value , 0.065). Data were then logged and
renormalized. For RMA normalization, all data were com-
piled using RMA Express, or RMA through R or BRBArray-
Tools.
MATRIX (MicroArray TRansformation In eXcel) is a
Microsoft Visual Basic program that allows import of multiple
CHP ﬁles (saved as text ﬁle format) from Affymetrix Micro-
Array Suite 5.0 into an Excel spreadsheet where median
normalization, comparison of arrays using log ratios and
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t-tests, color display, and hierarchical clustering can be
performed. Speciﬁcally, expression signals are ﬁrst log2-
transformed and color coded such that higher signals are
displayed as darker (blue) colors. Absent (high detection p-
value) signals are optionally coded separately on a gray scale.
For comparison of samples or classes of samples, log2 ratios
(i.e., difference of log2-transformed signals) are calculated. If
samples are compared, the stronger signals must have a
present call (detection p-value, 0.05). If classes of samples are
compared (as log ratios of the means), the median of the
detection p-values for the class with the highest mean
expression value must be less than 0.05. Two-sample t-tests
are further calculated to ﬁlter out univariate non-signiﬁcant
differential expression. Hierarchical clustering was performed
using average linkage with a Pearson correlation metric. All
analyses are performed using extensive gene annotation and
all probes are BLAST-veriﬁed. MATRIX has not been released,
as it is still under development. While this program was used
extensively in these studies, all analyses were reproduced using
publicly available software. Please contact Luc Girard (Luc.
Girard@utsouthwestern.edu) for further details.
Statistical Methods
ForCpG island enrichment analysis, intersect tables between
the relevant RefSeq gene lists andCpG island annotations were
generated using the Table Browser function at the Genome
Browser database (http: / /genome.ucsc.edu/cgi-bin/
hgTables?org¼Human&db¼hg17&hgsid¼73574615&
hgta_doMainPage¼1 ). Statistical signiﬁcance for the
resultant data was determined using the v2 method where the
expected value for 59 CpG islands for RefSeq annotations was
;37% based on the May 2006 genome build.
Statistical analysis for the primary tumor gene expression
data was based on the signiﬁcance analysis of microarray
(SAM) algorithm implemented through BRB ArrayTools,
developed by Richard Simon and Amy Peng Lam at NIH.
Statistical signiﬁcance of the methylation data was deter-
mined using the v2 method where appropriate.
Correlations between array and QPCR data were deter-
mined using the Pearson correlation coefﬁcient. Cluster
analysis was performed using Cluster and TreeView either
through BRB ArrayTools or directly. Agreement analysis for
biological replicate array data was performed as follows:
Affymetrix U133 Plus 2.0 .cel ﬁles were normalized using
RMA implemented through the ‘‘Affy’’ R package (version
1.8.1) from Bioconductor (http://www.bioconductor.org/
packages/bioc/1.7/src/contrib/html). To evaluate the consis-
tency of the most differentially expressed genes from
biological replicate experiments, we considered a gene to
be in agreement if in both experiments, the gene was up- or
down-regulated in the same direction compared to control.
The agreement analysis consisted of the following steps: (1)
calculate log2 for each cell line in each experiment:
(expression value of the treated cell)/(expression value of
the control cell of RMA-normalized data); (2) select the top
1,000 or 2,000 up- or down-regulated genes from each
experiment; (3) extract genes that were common to both
replicate experiments (union gene set), i.e., genes that were in
the top or bottom 1,000 or 2,000 genes in both experiments;
(4) calculate the proportion of genes in common for each
union dataset, which yields a point estimate for the
proportion of agreement: (# of pairs that move in the same
direction)/(# of pairs in the union set); (5) for each dataset
obtain 5,000 bootstrap samples drawn with replacement from
the original dataset; (6) calculate the median and 95%
conﬁdence interval (CI; 2.5% and 97.5%) for the agreement
proportion [35]. The total number of genes and expressed
sequence tags on the array was 54,675.
Enrichment analysis for gene ontology and chromosomal
location was performed using NIH-DAVID (http://david.abcc.
ncifcrf.gov/home.jsp), using text ﬁles containing accession
number lists of Affymetrix probe IDs or GenBank (http://www.
ncbi.nlm.nih.gov) accession numbers. Statistical enrichment
was determined using a Fisher’s exact test in which the null
hypothesis was that no difference exists between the number
of genes falling into a given ontology in the input list and the
genome as a whole [33].
Comparative Genome Hybridization Array
Cell line DNA was isolated using a phenol/chloroform
extraction and ethanol precipitation. Each cell line was
ﬁngerprinted prior to analysis to ensure that the cell lines
were properly identiﬁed. Comparative genome hybridization
array (aCGH) were performed as previously reported [16,36].
Results
Standardizing 5-Aza Treatment for HBECs and Cancer Cell
Lines
To analyze the gene expression changes associated with loss
of promoter methylation in lung cancer cells compared to
HBECs, we treated seven NSCLC cell lines (NCI-H460, H1299,
H157, H2347, H1819, H1993, and A549) and three HBEC lines
(HBEC2, 3, and 4) with low (100 nM) and high (1 lM) doses of
5-aza (Figure 1; Table 1). To determine whether low- and
high-dose 5-aza induced genes silenced by promoter methyl-
ation in NSCLC cell lines, we performed QPCR for p16. We
also ran standard reverse transcriptase-PCR for p16 in several
cell lines to ensure that the QPCR primer set did not amplify
the alternate splice-form, p14, which is expressed in some of
these cell lines [37]. We observed induction of p16 mRNA for
both low- and high-dose 5-aza in tumor lines that harbor p16
promoter methylation (Figure 2A and 2B). Since p16 could
not be used as a positive control for NSCLC lines with
homozygously deleted or unmethylated p16, we used the
universally methylated gene transketolase-like 1 (TKTL1) as a
positive control for loss of DNA methylation and gene
induction. TKTL1 was induced by 5-aza in all cell lines
examined (Figure 2A and 2C).
Microarray Analysis of Gene Expression Changes after 5-
Aza Treatment in Lung Cancer Cell Lines
We performed microarray expression proﬁling on the
seven NSCLC and three HBEC cell lines before and after
treatment with 100 nM and 1 lM doses of 5-aza, and
compared the resultant gene expression proﬁles. We con-
ﬁrmed our array data in three ways: (1) each cell line was
treated with 100 nM and 1 lM doses of 5-aza in a single
experiment to conﬁrm array reproducibility and the ability
of both doses to induce gene expression (Table 2); (2)
biological replication was performed on the three HBEC cell
lines 18 months apart on the U133 Plus 2.0 GeneChip, and on
four of the seven NSCLC cell lines on the U133A GeneChip,
and subsequently on the U133 Plus 2.0 platform (Table 3); (3)
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QPCR was performed on at least 15 genes in each cell line
and at each dose of drug (Table 4; unpublished data).
Currently, the thresholds of DNA methylation required to
establish gene silencing are unknown, and increasing doses of
5-aza may result in the activation of unrelated gene pathways.
However, it has been demonstrated that increasing doses of 5-
aza results in increasing levels of demethylation-dependent
gene induction [38]. Thus, we used two doses of 5-aza in our
array induction experiments. We found a highly signiﬁcant
relationship between both the genes induced in the two
treatments and those induced in a dose-dependent manner
(Table 2). We determined whether genes were reproducibly
inducible by 5-aza over long-term culture by comparing
replicates on different types of Affymetrix arrays (U133A
GeneChip and U133 Plus 2.0) for four of our seven NSCLC
cell lines (A549, H2347, H1299, and H157), as well as data
collected on the same type of chip for biological replicates
performed 18 months apart on the three HBEC lines.
Agreement between HBEC experiments performed 18
months apart was highly signiﬁcant (Table 3). Gene expres-
sion patterns across platforms also correlated well (Pearson
correlation coefﬁcients for overlapping gene sets on the two
platforms in independent experiments ranged from 0.90 for
H157 1 lM to 0.98 for H157 DMSO).
Our analysis of the gene expression proﬁles of lung cancer
cells before and after treatment with 5-aza identiﬁed 866 out
of 47,000 transcripts that were up-regulated at least 4-fold in
two or more lung cancer cell lines (Figure 1). Individually, the
cell lines exhibited substantial variations in expression
phenotype: H1819 had the fewest (268) genes induced at
least 4-fold, whereas H460 had the most (1,100) (Figures S1
and S2). The diversity in gene expression we observed may
derive from several factors, including etiology and histopa-
thology (Table 1).
To further validate the induction patterns observed by
microarray, we performed QPCR on 15 genes across all cell
lines (Table 4). We found that, with the exception of cathepsin Z
(CTSZ), QPCR analysis correlated well with microarray
expression changes. Disagreement between the array and
QPCR data for CTSZ likely derives from the sensitivity of the
Pearson correlation algorithm to small deviations above and
below a mean-centered value.
Isolation of Tumor-Specific Promoter Methylation
Candidates
To identify genes that are methylated speciﬁcally in cancer
cells, we performed similar induction experiments in three
HBEC lines. All three HBEC cell lines exhibited changes in
gene expression after 100 nM and 1 lM 5-aza treatment
(Figure S2A–S2D). In contrast to the cancer cell lines, the
Figure 1. Strategy Used to Identify Methylation Candidates by Gene
Expression Microarray
NSCLC and HBEC lines were treated with 5-aza and compared to controls
(DMSO). We subtracted transcripts induced at least 4-fold in HBEC (n ¼
133) from the total number induced at least 4-fold in two of seven NSCLC
lines (866 loci of 47,000 total), since methylation of these genes is
unlikely to be tumor specific. For practical purposes we removed genes
that were not expressed in HBEC (n ¼ 460), were duplicate probes (n ¼
11), or had poor annotations (n¼ 66). Finally we excluded genes without
identifiable 59 CpG islands (n ¼ 64). The number of genes subtracted
from the total induced 4-fold in two of seven NSCLC cell lines (n¼ 866)
is indicated next to each description in parentheses. We used the
percentage of transcripts associated with 59 CpG island as a measure of
enrichment for the major steps in the filtering process. 37% of all RefSeq
transcripts contain 59 CpG islands; 55% of the 866 5-aza–induced
transcripts had 59 CpG islands; 73% of the final 196 genes had CpG
islands. Statistical analysis of these data appears in Table 5.
doi:10.1371/journal.pmed.0030486.g001
Table 1. Clinicopathological Features of Cell Lines Used in Microarray Studies
Sample Name Cell Type Diagnosis Age, y Sex Smoker/Pack-Years
HBEC2 Bronchial epithelial NSCLC 68 M Y
HBEC3 Bronchial epithelial No cancer 65 F Y
HBEC4 Bronchial epithelial Lung cancer 71 F Y
A549 Lung cancer Adenocarcinoma 58 M Y
H460a Lung cancer Large cell ;45 M Y/;40
H1299 Lung cancer Large cell 43 M Y/50
H1819 Lung cancer Adenocarcinoma 58 F Y/80
H157 Lung cancer Squamous cell carcinoma 59 M Y/?
H1993 Lung cancer Adenocarcinoma 46 F Y/30
H2347 Lung cancer Adenocarcinoma 54 F N/0
H526 Lung cancer SCLC 55 M ?
MCF7 Breast cancer Adenocarcinoma 69 F N/A
HCT116 Colon cancer Colorectal carcinoma Adult M N/A
Data are from Phelps et al. [15]. All patients/participants were/are of Northern European descent except HCT116, whose descent was/is unknown.
aJDM, unpublished data.
doi:10.1371/journal.pmed.0030486.t001
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HBECs responded similarly to 5-aza treatment. Bioinformatic
analysis of the genes induced at least 4-fold in the HBECs
suggests that many may be expressed speciﬁcally during
development or only in certain tissues (Figure S3; Table S1).
Beginning with the 866 transcripts that were induced 4-
fold or more in at least two NSCLC cell lines, we excluded 133
that were induced at least 4-fold in HBECs, and we required
that a given gene was expressed at a robust median level
(MAS5 normalization procedures were used because this
method gives an indication of whether a given probe signal is
present or absent) in the HBECs with an Affymetrix p-value 
0.065. Of the remainder, 460 were excluded on the basis of
low (undetectable) expression in the untreated HBEC lines.
We further ﬁltered this list of genes by excluding 66 genes
without deﬁned 59 ends or that were otherwise poorly
annotated, and 11 that were duplicate probes. This left 196
Figure 2. 5-Aza Treatment Induces Genes Silenced by Promoter Methylation in HBEC and NSCLC Cell Lines
(A) QPCR for p16 and TKTL1 in HBEC and NSCLC. Solid bars are p16 and cross-hatch bars are TKTL1. Data are normalized, relative mRNA expression levels
according to the 2DDCt method. HBEC2, 3, and 4 had similar profiles and were combined; data are averages and error bars are6 standard deviation. p16
status is indicated below each cell line;þ, expressed; HD, homozygous deletion; M, methylated.
(B) RT-PCR for p16 in the indicated cell lines. GAPDH is a loading control.
(C) Methylation-specific PCR for TKTL1 in the indicated samples shows complete methylation in all samples examined, both methylated (M) and
unmethylated (U). SssI in vitro-methylated DNA was used as a positive control for the methylated primers, and 5-aza-treated DNA was a positive control
for the unmethylated primer sets (for PCR conditions and primer sequences see Protocol S1).
doi:10.1371/journal.pmed.0030486.g002
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genes that were induced in the NSCLCs and that met the
various ﬁltering criteria.
5-Aza can affect the expression of genes independent of
their methylation status [39]. Before restricting the gene set
to those with CpG islands, we asked whether our approach
had identiﬁed a set that was enriched for genes associated
with 59 CpG islands. The null hypothesis was that our
selection criteria would make no difference on the frequency
of selecting a gene with a CpG island. The expected rate for a
RefSeq annotated gene to contain a 59 CpG island (.500 bp
in length) within 2 kb of its transcription start site is ;35%
[40]. Based on the March 2006 build, ;37% of the RefSeq 59-
UTR annotations contain 59 CpG islands within 500 59 bases.
The 866 transcripts we identiﬁed on the basis of their
induction pattern in NSCLC alone contained 435 RefSeq
annotations, while 132 of the 196 transcripts that remained
after ﬁltering out genes as described above (Figure 1) had
RefSeq annotations. Both of these groups had signiﬁcant
increases in CpG frequency (Table 5).
On the basis of these data, we examined each of the 196
genes and excluded those that did not have CpG islands
deﬁned as larger than 300 bp, a GC content of 55% or more,
and an observed versus expected CpG ratio of 0.65 or higher.
The remaining 132 transcripts correspond to genes (listed in
Figure 3; Table S2) that are candidates for tumor-speciﬁc
methylation in NSCLC on the basis of their expression
pattern in HBECs (i.e., were expressed) and lung cancer cell
lines (i.e., were not expressed in several lines), their response
to 5-aza in lung cancer cells (induced 4 fold), and the
presence of a 59 CpG island (Figure 3).
Expression Patterns of the 5-Aza Induction Gene Set in
Lung Cancer Versus Normal Lung
Although other gene sets were of interest—such as those
induced by 5-aza in the HBEC lines, but expressed in the
NSCLC panel (i.e., candidate genes that may have undergone
tumor-speciﬁc promoter hypomethylation and thus function
as oncogenes)—in this study we focused on genes that were
likely to have undergone tumor-speciﬁc promoter hyper-
methylation leading to inactivation of their expression. We
ﬁrst determined whether our 5-aza induction gene set
reﬂected the gene expression phenotype of a broader set of
NSCLC cell lines and HBECs. Using Affymetrix microarray
mRNA expression data for NSCLC cell lines (n ¼ 31;
combined U133A and B chips) and HBEC (n ¼ 7; U133 Plus
2.0) lines, we found that all HBEC lines express relatively high
levels of these genes, but the lung cancers, while of diverse
histologies, express much less (overlap between U133A and B
chips with U133 Plus 2.0 included 117 unique genes) (Figure
4). These results suggest that loss of expression of the genes in
the 5-aza induction gene set is a common event in NSCLC.
To determine whether the expression patterns we identi-
ﬁed in vitro accurately represent those identiﬁed by micro-
array expression proﬁling in primary lung cancers, we
explored whether the 5-aza induction gene set could
distinguish uncultured normal lung from primary lung
cancer in two separate microarray datasets. These data are
derived from different lung tumor sources (see Methods)
collected over a period of several years and comprise
expression phenotypes for primary NSCLC (n ¼ 45) and
counterpart normal lung (n¼29), and were randomly selected
from a larger panel of array samples. After extracting the
relevant probes and ﬁltering the data, we found that the
majority of genes were on average expressed at higher levels
in the normal samples. While marked gene expression
differences between NSCLC and normal lung are to be
expected, the 5-aza induction gene set clearly distinguished
these phenotypes in our data (Figure 5). Of 117 unique genes
in this group, 94 were differentially expressed between tumor
and benign tissue based on the SAM algorithm (90th
percentile conﬁdence, false discovery rate among the 94
signiﬁcant genes was 0.11 and the delta value used to identify
signiﬁcant genes was 0.54) (Table S3).
Tumor-acquired promoter methylation often coincides
with allele loss. To determine whether any of the 132
candidate genes were also subject to copy number losses, we
analyzed aCGH data for the same panel of NSCLC cell lines
that were used for the microarray studies (n¼ 31). Of the 132
genes, approximately half (58/132) had corresponding probes
with high-quality data on the Stanford aCGH platform. Of
Table 2. Reproducibility and Dose-Dependence of Gene
Induction by 5-Aza-29-Deoxycytidine
Cell
Line
Genes Induced
4-Fold
by 5-Aza, n
Up in
Botha
1 lM .
100 nMb
p-Valuec
100 nM 1 lM
HBEC2 602 591 99.7% 357 6.07 3 106
HBEC3 148 289 96.6% 106 2.24 3 107
HBEC4 88 219 100% 72 1.19 3 109
H2347 127 387 99.2% 77 2.1 3 102
H1299 74 402 100% 64 8.96 3 1011
A549 60 188 96.7% 56 9.08 3 1013
H1993 11 80 100% 11 9.77 3 104
H157 114 416 98.2% 100 1.72 3 1015
H460 27 501 100% 27 1.49 3 108
H1819 25 67 100% 24 1.55 3 106
aA given gene was ‘‘up in both’’ if it was induced at least 4-fold in the 100 nM experiment
and was induced any amount in the 1 lM experiment.
bA given gene was counted as dose-dependent when induction relative to control was at
least 4-fold in the 100 nM array and 1 lM induction was . 100 nM for the same gene.
cp-Value for 1 lM . 100 nM was determined using a sign test; the null hypothesis was
that there would be no relationship between dose and level of gene expression between
high- and low-dose 5-aza.
doi:10.1371/journal.pmed.0030486.t002
Table 3. Agreement and 95% CIs for Biological Replicates
Performed 18 Months Apart
Cell Line Genes Compared Overlapa Point Estimate (95% CI)
HBEC2 Top 1,000 1,620 0.746 (0.724–0.767)
Top 2,000 3,291 0.711 (0.695–0.727)
HBEC3 Top 1,000 1,682 0.762 (0.741–0.782)
Top 2,000 3,431 0.711 (0.695–0.726)
HBEC4 Top 1,000 1,606 0.810 (0.790–0.829)
Top 2,000 3,278 0.732 (0.717–0.747)
aAgreement analysis was performed as described in Methods. Comparisons were made
between the top 1,000 and 2,000 genes for each replicate at 1 lM compared to control
(DMSO). The overlap is the number of genes that are coincident between the two
replicates: 2,000 are possible for the top 1,000, and 4,000 are possible for the top 2,000.
doi:10.1371/journal.pmed.0030486.t003
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these, 62% (36/58) exhibited a net (median) allele loss across
the panel of 31 NSCLC lines (unpublished data; JRP et al.,
personal communication) (Figure 6). Thus, beginning with 5-
aza induction data in lung cancer, we identiﬁed 132 genes
with 59 CpG islands that are differentially expressed in
primary lung cancer compared to normal lung tissues, many
of which are also subject to frequent copy number losses in
corresponding NSCLC lines.
Methylation Analysis of 45 of 132 5-Aza Induction
Candidates in Lung Cancer Cells, HBEC Lines, and Normal
Peripheral Blood Cells
To determine whether the genes identiﬁed in our screen
are methylated in lung cancer cell lines, we designed MSP
primer sets (methylated and unmethylated speciﬁc) for 45 of
132 candidate genes as well as two control gene primer sets,
and tested these on the seven NSCLC lines used for the 5-aza
induction studies (for primers, setup, and protocols, see
Methods and Protocol S1). As determined by MSP, between
19 and 25 genes out the 45 loci were methylated in any given
tumor cell line, whereas at most seven were methylated in the
HBECs (Figure 7); several loci were positive for both
methylated and unmethylated alleles, consistent with pre-
vious studies [41].
As an additional control for tumor-speciﬁc methylation,
and to determine whether these markers might be useful in a
clinical setting, we tested whether any of the genes were
methylated in DNA derived from peripheral blood cells
(PBCs) of unaffected individuals. This control is important
because PBCs are almost always present in biopsy specimens,
and the presence of methylation in these cells would preclude
use of a given marker for patient screening purposes.
Although we found different promoter hypermethylation
proﬁles between different sources of PBCs (unpublished
data), in this study a gene promoter was counted as
methylated if there was a methylated product in any source
of PBCs. By this criterion we found that 11 genes were
methylated in at least one PBC source. We grouped the genes
according to their methylation patterns as follows: genes with
tumor-speciﬁc methylation (group I; 31 genes); genes with
some methylation in HBECs, but not in normal lymphocyte
DNA (group II; ﬁve genes); and genes with methylation in
PBC DNA (group III; 11 genes).
Methylation Analysis of 45 of 132 5-Aza Induction Gene
Set in Primary Lung Cancers and Normal Lung
It has been suggested that tumor cell lines acquire
methylation in culture and as a result may not accurately
reﬂect the methylation patterns of tumors in vivo [5,41]. To
address this issue, and to determine whether any of the
markers we found were methylated in primary tumor
samples, we tested all 45 markers in 20 matched pairs of
primary NSCLC and counterpart normal lung tissue (Figure
6). The frequency of methylation in a given tumor ranged
from 33 to 17 of the 45 genes. When all genes were included,
methylation was signiﬁcantly more frequent in the matched
tumor sample (p , 0.001, paired t-test). Basonucleolin (BNC1)
and lysyl oxidase (LOX) were methylated in nearly all of the
primary tumors examined, but were not methylated in
normal PBCs, and infrequently in normal lung; in compar-
ison, p16 and RASSF1A were methylated in this same NSCLC
panel at rates of 30% and 40%, respectively [18]. The
appearance of low-level methylation in some normal counter-
part tissue may result from ﬁeld effects and/or tumor cell
contamination. Some markers were methylated at high
frequency in tumors (.30%; compared to p16 and RASSF1A,
30% and 40%, respectively) and never in matched normal
tissue such as CTSZ and placental growth factor (PGF).
In general, the methylation frequency of group I genes was
similar to that of the cell lines used in this study; where there
was frequent methylation in the cell lines, there was frequent
methylation in the primary tumors (Figures 6 and 7). Group II
and III genes also followed the patterns identiﬁed in the cell
Table 4. Correlation between Microarray and QPCR Data
Gene Induction
Frequency
(n of Seven)a
Range of
Expression
Changeb
Pearson
Correlation
Coefficient
Array QPCR Array QPCR
ADRB2 2 5 0.81 to 2.71 0 to 3.66 0.829
ALDH1A3 2 5 0.56 to 3.88 0.00 to 3.31 0.333
BNC1 6 7 1.40 to 8.40 1.48 to 12.06 0.892
CCNA1 5 5 1.06 to 6.76 1.03 to 6.6 0.965
CDH1 2 5 1.63 to 5.17 1.91 to 7.10 0.603
CTSZ 2 4 1.56 to 2.38 0.44 to 1.56 0.181
IRX4 3 6 0.31 to 5.78 2.14 to 17.09 0.978
LOX 3 5 2.05 to 2.45 2.16 to 44.42 0.932
MAF 2 5 1.61 to 2.26 0.26 to 14.31 0.906
NRCAM 3 5 0.39 to 2.44 0.74 to 6.37 0.807
PHLDA1 3 3 0.43 to 2.28 0.12 to 3.34 0.758
aInduction frequency is the number of cell lines out of seven in which a given gene was
induced at least 4-fold.
bExpression change is indicated in log2
doi:10.1371/journal.pmed.0030486.t004
Table 5. Analysis of CpG Island Enrichment for Genes Induced by 5-Aza in Microarray Experiments
Gene List RefSeq Annotation 59 CpG Island No CpG Island Percentage with
CpG Island
v2 v2 Monte Carlo (105)
All RefSeq 17,820 6,704 11,116 37.6% N/A N/A
Up in NSCLC 435 240 195 55.2% 4.1 3 1014 1 3 105
5-Aza induction 134 98 36 73.1% 2.2 3 1016 1 3 105
Intersect tables were downloaded from the UCSC genome browser for each annotation list using the May 2006 genome build. Chi-square statistics were determined using the expected
value of 37.6% with one degree of freedom. The Monte Carlo method was used to simulate samples of various sizes with 100,000 represented here.
doi:10.1371/journal.pmed.0030486.t005
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lines; where methylation was found in the HBECs, methylation
was frequent in both primary tumors and matched normal
lung.Whenmethylationwas detected in normal PBCDNAand/
or HBEC DNA, methylation was evident in both primary
tumor and normal lung DNA samples (which has PBC
contamination). While all of these genes could be involved in
lung cancer pathogenesis through promoter methylation and
concomitant loss of expression, we focused on the 31 group I
Figure 3. 5-Aza-Induced Gene Set in NSCLC, SCLC, Breast, and Colon Cancer Cell Lines
Heat map for gene induction across NSCLC and other cancer cell lines as indicated. Data are log2 changes between mock-treated and 1 lM 5-aza
treatment in each cell line. Bright red indicates 4-fold or greater up-regulation; intermediate red, at least 2-fold induction; grey, less than 2-fold
induction; black, no data. The data are ordered from top to bottom according to the frequency of 4-fold induction across the NSCLC cell lines. The
vertical colored bars parallel to the heat map represent the frequency of 4-fold induction in the NSCLC 5-aza induction experiments. Affymetrix probe
IDs, GenBank accessions, UCSC cytoband alignment, and gene symbols are represented in order from top to bottom with the colored bars from the
heat map indicating fold induction; purple indicates five of seven, blue indicates four of seven, green indicates three of seven, and yellow indicates two
of seven. The figure layout was borrowed from [66].
doi:10.1371/journal.pmed.0030486.g003
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Figure 4. Complete-Linkage Cluster Analysis of 5-Aza-Induced Methylation Candidates in NSCLC and HBECs
Analysis was performed on a panel of 31 NSCLC cell lines (U133A and B) and seven HBEC lines (U133 Plus 2.0) with an overlapping gene set (117 genes).
Data are mean-centered log2 expression values across the samples. Red indicates above the mean; green, below the mean. The 5-aza induction gene set
separates cancer from HBEC lines and in most cases these genes are expressed at high levels in HBECs but not in NSCLC.
doi:10.1371/journal.pmed.0030486.g004
Figure 5. Complete-Linkage Cluster Analysis of 5-Aza-Induced Methylation Candidates in NSCLC and Normal Lung Tissues
Panel included 46 primary NSCLC samples and 29 counterpart normal lung tissues. Arrays are median-centered and genes are mean centered and
colored as in Figure 4. Blue bar indicates normal lung; purple bar indicates tumor tissue. The 5-aza induction gene set clearly distinguishes cancer from
normal. Most genes are expressed at higher levels in normal tissues, although not all.
doi:10.1371/journal.pmed.0030486.g005
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genes as being the best candidates for diagnostic markers to
avoid genes found to be methylated in normal lung or PBCs.
Comparison of 5-Aza Induction Gene Expression Profiles
in Breast Cancer, Colon Cancer, and Small Cell Lung
Cancer Cells
While there was some overlap between genes induced by 5-
aza among the NSCLC lines, the predominant pattern we
found reﬂects signiﬁcant expression differences within the
same tissue type (Figure S3). The diversity we observed in
NSCLC led us to explore whether other epithelial cancers
differ dramatically in their response to 5-aza. We performed
the 5-aza induction experiments in breast cancer, colon
cancer, and small-cell lung cancer (SCLC) cells using our
standard protocol with a minor modiﬁcation for the non-
adherent SCLC cell line (see Methods). When we compared
Figure 6. Summary of Methylation-Specific PCR in Matched Primary NSCLC and Adjacent Nonmalignant Tissue
Data are color-coded and grouped as follows: red fill indicates positive methylated product; blue indicates positive unmethylated product. Data are
grouped as follows: group I, no methylation in either HBECs or PBC DNA; group II, methylation in HBECs but not PBCs; group III, methylation in PBCs.
Data are ordered from top to bottom according to the frequency of methylation in primary NSCLC. ‘‘GENE’’ indicates gene symbol; blue bars indicate
loss of heterozygosity (LOH; allele loss) (a net [median] copy number change over 31 cell lines was calculated by taking the median signal over all cell
lines); grey, no data; black, control primer sequences. Data are presented in the same order in the top (methylated) and bottom (unmethylated) panel.
doi:10.1371/journal.pmed.0030486.g006
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these cell types after 5-aza induction by (SAM) and cluster
analysis, we found that although each cell line clustered with
itself independent of treatment, SCLC and breast cancer
cells, but not the colon cancer cell line HCT116, clustered
apart from NSCLC (Figure S4). However, after supervised
hierarchical cluster analysis using our ﬁnal 5-aza induction
gene set, tissue-of-origin distinctions were no longer appa-
rent (Figure S5). These data suggest that part of the 5-aza
induction response in these cell lines may be independent of
tissue-speciﬁc gene expression or promoter methylation
proﬁles.
To further explore the ﬁnding that 5-aza induction
patterns in cancer cell lines may be independent of tissue
of origin differences, we compared our dataset to those of
Sato et al. [41], who used the Affymetrix U133A chip to
examine gene induction patterns after 5-aza treatment in
four pancreatic cancer cell lines. The authors reported that
475 genes were up-regulated over 5-fold in at least one cell
line. Of these 475 genes, 203 were also up-regulated in at least
one of our cell lines, with 127 up-regulated in two or more
(Table S4). Bioinformatic analysis of the overlapping gene set
between the Sato et al. and our data indicates some highly
signiﬁcant similarities in the position of the genes induced by
5-aza in lung and pancreas (Table S5), but unfortunately
robust statistical analysis of this ﬁnding was not possible due
to the unavailability of the raw data and differences in
experimental setups. Multiple genes in two chromosomal
regions, Xp11.2–11.4 and 6p21.3, were induced in both types
of cell lines, and, based on the gene density in these genomic
regions, each enrichment was highly signiﬁcant (p ¼ 3.01 3
109 and p ¼ 1.013 107, respectively, Fisher’s exact test).
Next we analyzed the expression pattern of the 5-aza
induction gene set across a panel of breast cancer cell lines
and found that for the 5-aza induction panel (by average
linkage cluster analysis), most of the lung cancer cells and
approximately half of the breast cancers fall into a major
cluster distinct from the remaining breast cancer cells and
the immortalized HBECs, which form their own tight cluster
with a minimum Pearson correlation coefﬁcient of greater
than 0.7 (Figure S6). These data suggest that tumor-speciﬁc,
Figure 7. Summary of Methylation-Specific PCR in HBEC and NSCLC Cell Lines
From the left, Locus Link ID (LL ID), gene symbol (GENE), in vitro methylated (SssI) DNA mixed with lymphocyte DNA, normal PBC DNA, HBEC lines,
NSCLC cell lines, as indicated. Red fill indicates positive methylated product; blue indicates positive unmethylated product. Data are grouped as follows:
group I, no methylation in either HBECs or PBC DNA; group II, methylation in HBECs but not PBCs; group III, methylation in PBCs. Data are ordered by
the frequency of methylation in primary lung tumors (Figure 6).
doi:10.1371/journal.pmed.0030486.g007
PLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e4862256
Novel Methylation Markers in Cancer
rather tissue-speciﬁc, gene expression patterns are the
predominant factor driving the clustering algorithm for the
5-aza induction gene set. To conﬁrm these ﬁndings, we
examined 15 of the genes found to be frequently induced by
5-aza and methylated in NSCLC in six breast cancer cell lines
(HCC3153, HCC1143, HCC1937, SKBR3, ZR-75–1, and MCF7)
and found nearly all to be induced by 5-aza in these cells
(Table 4; Figure S7). The overlap we found in the gene
induction patterns between NSCLC, SCLC, breast, and colon
cancer cells in our 5-aza induction microarray experiments,
those in our breast cancer cell line panel, and those
previously reported in pancreatic cancer cells suggested to
us that some of these genes may be methylated in breast
cancer and other cancers [42].
Methylation Analysis of Select Genes in Primary Breast
Cancer and Counterpart Normal Tissue
We selected eight of 15 markers that were induced by 5-aza
in both lung and breast cancer cells for analysis in primary
breast tumor material. Of the primary breast tumors used in
this study, 23 form part of a large dataset used in several
studies in which fundamental histological and phenotypic
differences were deﬁned between subtypes of ductal breast
carcinomas [43]. The DNA from these samples was derived
from bulk tumor specimens upon surgical resection from the
primary tumor site, metastatic sites, or at autopsy. With one
exception, all of these tumor specimens were stage IIB or
later. We found that among the eight genes tested in 23 breast
carcinomas, seven were frequently methylated (60%–90%)
(Figure 8). These breast cancer samples did not have
counterpart normal tissue.
To address whether methylation for these eight genes was
detectable in benign breast tissue, an additional 14 tumor
samples that have matched benign material were examined
(see Methods); these samples are primarily early-stage tumors
(stage IIB or earlier) collected upon surgical resection of the
primary tumor. The counterpart benign tissue was collected
by FNA in the ipsilateral breast (except where indicated) and
have not been described previously. As with the later stage
breast tumor samples methylation was common, although
overall there was more methylation in the more advanced
tumor stage group. Only SOX15 exhibited frequent methyl-
ation in benign breast material (Figures 8 and 9; Table 6).
Methylation-speciﬁc PCR, while robust, is extremely
sensitive and can detect methylated sequences in the
presence of large amounts of unmethylated DNA. We used
sodium bisulﬁte DNA sequencing to conﬁrm that the MSP
primer sets used in these studies ampliﬁed the appropriate
target sequences and that these sites were bona ﬁde hyper-
methylated CpG islands. We designed primers that ﬂank the
MSP priming sites for the eight genes examined and then
cloned and sequenced PCR products from bisulﬁte-treated
HBEC and/or lymphocyte DNA and tumor cell DNA. Between
eight and 20 subclones from each selection plate for each cell
type and gene were analyzed. With the exception of NRCAM,
all sequences were heavily methylated in the tumor cells but
not in HBEC or PBC DNA (Figures S8–S14 and 8). Based on
these data, and its infrequent methylation in breast cancer,
we excluded NRCAM from subsequent analyses.
Figure 8. Summary of Sodium Bisulfite Sequencing for Seven Genes in PBCs, HBECs, and NSCLC Cells
Between eight and 20 clones were sequenced for each locus in each cell type. Sequencing primers were designed to flank the MSP priming sites and do
not include any CpG sites, with the exception of BNC1, which we were not able to amplify outside of the MSP priming sites for cells that harbored
methylation. There was no amplification of the methylated primer set in HBECs or PBCs, and no amplification of the unmethylated primer set in the
NSCLC cell lines examined. One some occasions the methylated primer set for BNC1 amplified a 289 bp amplicon from an unrelated locus on
Chromosome 1. The sequence corresponds to a CpG island in an intronless gene (GPR25) that was heavily methylated in tumors. The unmethylated
primer set did not amplify this sequence. Each box represents a composite of clones for that CpG site. Open boxes indicate 0%–25% methylation; light
grey, 26%–50%; dark grey, 51%–75%; black, 76%–100% methylation. Raw data are available in Figures S8–S14. Primers and PCR conditions are available
upon request.
doi:10.1371/journal.pmed.0030486.g008
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Examination of the Methylated Gene Set in Matched Pairs
of Colon and Prostate Cancers and Companion Benign
Epithelium
Tumor-speciﬁc promoter hypermethylation is often also
tissue-speciﬁc. To explore whether the seven genes (BNC1,
LOX, ALDH1A3, MSX1, CCNA1, CTSZ, and SOX15) we
identiﬁed in the previous section were methylated in other
tissues besides breast and lung, we examined an independent
set of primary colon and prostate cancers and their matched
normal tissues. For comparative purposes we included
methylation data for p16 and RASSF1A for all tumor types
examined (Figure 10; Table 6). Data for RASSF1A and p16 are
derived from published work as annotated in the legend for
Table 6 [18,25,42,44–47].
BNC1, MSX1, and CCNA1 were frequently methylated in all
four tumor types. However, CCNA1 exhibited signiﬁcant
methylation in benign prostate and colon tissues. This
suggests that CCNA1 may undergo tissue-speciﬁc methylation
during cellular differentiation in certain tissues but not
others. BNC1 and MSX1 showed high sensitivity and
speciﬁcity for tumors when compared to benign counterpart
tissues (estimated values [95% CIs]: 0.81 [0.75 to 0.86] and 0.67
Figure 9. MSP for Indicated Genes in Ductal Breast Carcinoma DNA for Samples Obtained from UNC
The basal phenotype is based on gene expression profiles demonstrated previously and is characterized by the absence of estrogen receptor and a
poor prognosis. Other samples are characterized as luminal. Visible bands corresponding to the appropriate size were counted as positive. 100 bp
ladder is at far left. M, methylated product; U, unmethylated product.
doi:10.1371/journal.pmed.0030486.g009
Table 6. Frequency of Promoter Hypermethylation for Eight Genes as Determined by MSP for Indicated Tumors
Diagnosis LOX MSX1 BNC1 CTSZ ALDH1A3 CCNA1 NRCAM SOX15
Count % Count % Count % Count % Count % Count % Count % Count %
Breast tumora 16/23 70% 21/23 91% 19/23 83% 14/23 61% 17/23 74% 12/23 52% 4/23 17% 23/23 100%
Lung tumor 19/20 95% 11/20 55% 18/20 90% 10/20 50% 9/20 45% 14/20 70% 18/20 90% 17/20 85%
Lung benign 4/20 20% 3/20 15% 3/20 15% 0/20 0% 3/20 15% 7/20 35% 8/20 40% 15/20 75%
Breast tumorb 5/14 36% 11/14 79% 9/14 64% 6/14 43% 4/14 29% 6/14 43% ND ND 11/14 79%
Breast benignb 0/14c 0% 5/14

35% 0/14

0% 0/14 0% 0/14 0% 1/14 7% ND ND 8/14 57%
Prostate tumor 0/24 0% 20/24 83% 18/24 75% 0/24 0% 5/24 21% 19/24 79% 3/24 13% 24/24 100%
Prostate benign 0/24 0% 10/24 42% 9/24 38% 0/24 0% 7/24 29% 6/24 25% 1/24 4% 21/24 88%
Colon tumor 0/24 0% 21/24 88% 22/24 92% 0/24 0% 11/24 46% 24/24 100% 7/24 29% 24/24 100%
Colon benign 0/24 0% 13/24 54% 10/24 42% 0/24 0% 7/17 29% 23/24 96% 4/24 17% 20/24 83%
Numbers in bold face indicate a statistically significant difference in methylation frequency between tumor and normal samples according to a v2 statistic (p , 0.05). Tissue procurement
procedures and clinical information for samples may be found in the Methods section. In brief, all prostate and colon tumors were stage II or later, lung tumors ranged from stage I to IIIB.
For breast tumors, see footnotes, below. Benign tissue was obtained from the same patient in all cases except for the UNC samples; see footnotes, below, and Methods.
aBreast tumor samples were obtained through a collaboration with Chuck Perou at UNC. Samples in this group were all stage IIB or higher, with the exception of a single stage I tumor.
bBreast tumor samples were obtained though a collaboration with David Euhus at UT Southwestern Medical Center. All samples in this group were stage IIB or lower.
cBenign breast samples were obtained from the ipsilateral breast except for one sample for LOX and BNC1 and two samples for MSX1, which were obtained from the contralateral breast in
the same patient.
doi:10.1371/journal.pmed.0030486.t006
PLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e4862258
Novel Methylation Markers in Cancer
[0.60 to 0.75], respectively). For BNC1 and MSX1, both
prostate and colon benign tissues did have some methylation,
but the pattern was different from CCNA1. ALDH1A3 was
speciﬁcally methylated in all tumor types, albeit less
frequently than BNC1 or MSX1, showing the highest
sensitivity in breast and prostate and highest speciﬁcity in
lung. LOX and CTSZ methylation was restricted to lung and
breast tumors, and in both cases were highly speciﬁc. SOX15
was methylated in most benign tissues and has been omitted
from the histogram for clarity.
Discussion
We used global gene expression proﬁling (47,000 tran-
scripts) of seven lung cancer cell lines before and after
treatment with 5-aza to identify genes that were signiﬁcantly
up-regulated by this treatment. We performed similar
experiments in three newly available immortalized HBEC
lines to identify genes whose expression was selectively lost in
lung cancer, expressed in normal lung epithelium, but
inducible by 5-aza treatment. To our knowledge the use of
these cells as part of a global methylation induction screen
has not been described previously. We applied a series of
biological ﬁlters to extract a list of methylation candidates,
and statistical analyses of the major steps in this process
suggested that successive lists were enriched for genes with 59
CpG islands. Only those genes that were induced in more
than one lung cancer and had well-deﬁned CpG islands in
their putative promoter regions were selected. This ﬁltering
process led us to identify 132 candidate genes, 45 of which we
investigated in detail in the current study.
The large majority of the 132 genes we have identiﬁed have
not been described to undergo tumor-speciﬁc promoter
hypermethylation and expression of these genes distinguishes
primary lung cancers from normal lung in the same patient.
While many genes are probably methylated—perhaps at
random—during carcinogenesis, we found that 31 of the 45
genes studied here undergo tumor-speciﬁc methylation in
multiple primary lung cancers. We studied eight of these 45
genes in a panel of 105 primary tumors from NSCLC, breast,
colon, and prostate cancers and 82 histologically normal
companion tissues, which showed that these genes undergo
methylation in common epithelial cancers. Frequent methyl-
ation of speciﬁc genes in multiple independent cancers
strongly suggests but does not prove that these genes are
functionally relevant to cancer pathogenesis.
One goal of this study was to identify new genes involved in
tumor-speciﬁc methylation for follow-up functional analysis.
To this end, our screen uncovered some well-established
methylation markers that have tumor suppressor activity,
including TIMP3, CDH1, and SFRP1, but missed others such as
p16 and RASSF1A. That we missed some of the classical
methylation markers highlights a limitation of current
microarray technology: commercial arrays cannot always
discriminate between alternative splice forms of genes; both
p16 and RASSF1 have constitutively expressed alternative
isoforms that can hybridize to probes speciﬁc for these loci.
Since both genes have expressed isoforms (p14 and RASSF1C)
that differ only in their 59 regions, none of the probes speciﬁc
to these genes detected differences in expression. This
limitation means that we have probably missed isoforms of
genes that are subject to tumor-speciﬁc methylation, but that
are part of an active transcription locus.
Most of the genes identiﬁed in this study are novel
methylation candidates in NSCLC, although methylation of
some of them has been described in other tissues. LOX was
frequently methylated in our panel of cell lines and NSCLC
tumors, and was recently shown to be methylated in gastric
cancers [48]. CCNA1 was shown to be methylated in head and
neck cancers and was inversely correlated with p53 mutation
[49]. In our study, CCNA1 was methylated in A549, which has
wild-type p53, but was not methylated in NSCLC cells with
mutant p53. Loss of dual-speciﬁcity phosphatase I (DUSP1)
expression as determined by immunohistochemistry inversely
correlates with increasing malignancy of prostate cancers,
and methylation of its promoter appears to be an early event
in this disease [50]. In another recent report, tissue factor
pathway inhibitor 2 (TFPI2) methylation was used as part of a
six-gene panel to screen for cancer in pancreatic juice
specimens [51]. Promoter methylation of the transcription
Figure 10. Histogram for Methylation Frequency of Indicated Genes in Prostate, Breast, Lung, and Colon Cancer and Companion Normal Tissue
MSP data for indicated genes in breast (n¼ 14; red bars), lung (n¼ 20; black bars), prostate (n¼ 24; pale yellow bars), and colon (n¼ 24; grey bars)
tumors and benign tissue (see Methods). Only samples with matching benign and tumor tissue are represented in the histogram. Gels were run and
scored as above. SOX15 was omitted from this figure for clarity. Data for RASSF1A were obtained from [17,24,45,46]; data for p16 were obtained from
[17,43,44,46].
doi:10.1371/journal.pmed.0030486.g010
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factor TWIST1 has been described in several reports and is
frequent in neuroblastoma, cervical, and breast cancers,
although high expression of TWIST1 seems to be necessary
for breast cancer metastasis [52–55]. The proapoptotic BCL2
family member BIK was identiﬁed in a global screen for
promoter methylation in multiple myeloma using restriction
landmark genomic scanning [56].
Our data suggest that some genes, such as CCNA1, undergo
both tissue-speciﬁc and tumor-speciﬁc methylation. Tissue-
speciﬁc promoter hypermethylation arises in response to both
extrinsic and intrinsic signals during cellular differentiation
and may account for the distinctive methylation pattern we
observed for this particular cyclin [57]. The biological basis of
frequent tumor-speciﬁc hypermethylation in multiple tissues
coincident with tissue-speciﬁc methylation in another tissue is
unknown. However, two well-characterized tumor suppres-
sors, p16 and RASSF1A, exhibit similar tumor-speciﬁc and
tissue-speciﬁc promoter methylation proﬁles; p16methylation
is frequently observed in benign breast tissue, even in young
women, andRASSF1A promoter hypermethylation is observed
in benign liver and colonic epithelium [45,58]. Thus, the
presence of promoter methylation in selected normal tissues
does not exclude a gene from being an important tumor
suppressor. Nevertheless, the information on such methyl-
ation is important for clinical applications.
Another pattern of promoter hypermethylation evident in
our data, exempliﬁed by LOX and CTSZ, is characterized by
frequent but exclusive methylation in certain tumor types.
According to data available through various online databases
such as Genecard (Weizmann Institute [http://genome-www.
stanford.edu/genecards/index.shtml]) and Source (Standford
University [http://genome-www5.stanford.edu/cgi-bin/source/
sourceSearch]), both LOX and CTSZ are widely expressed.
Both genes also have several homologs that may be partially
redundant, or they may have tissue-speciﬁc functions
important to tumorigenesis in breast and lung, but not in
prostate or colonic epithelium. Several other genes exhibit a
similar, restricted methylation proﬁle, such as breast cancer 1,
early onset (BRCA1) in breast and ovarian tumors, and
glutathione S-transferase pI (GSTP1) in liver and prostate cancers
[59,60]. Genes that are methylated with high frequency and
speciﬁcity only in certain tumors would be valuable in the
development of a promoter hypermethylation proﬁle to
screen for several cancers in parallel.
Perhaps themost important proﬁle identiﬁed in this study is
that of tumor-acquired methylation involving the four most
common epithelial tumors. When all matched tumors were
combined, BNC1 and MSX1 were both highly sensitive and
speciﬁc for tumor detection. As yet, relatively few loci have
been identiﬁed that exhibit frequent (.50%), tumor-speciﬁc
methylation across several types ofmalignancies. Several genes
exhibit frequentmethylation inNSCLCandother tumor types,
such as the tumor suppressor gene adenomatosis polyposis coli
(APC) or retinoic acid receptor beta (RARb), but these genes are
often also methylated in counterpart benign tissue, especially
in tumors for which ﬁeld effects are common, such as NSCLC
[18,61]. The identiﬁcation of more loci like BNC1 and MSX1
will be an essential element to developing a promoter hyper-
methylation proﬁle for the early detection of human cancer.
Relatively few tumor-speciﬁc lesions occur with signiﬁcant
frequency in all types of tumors, with the important
exceptions of p53 mutation, genomic instability, and con-
stitutive reactivation of telomerase [62–64]. The wealth of
data available in the scientiﬁc literature suggests that
aberrant DNA methylation may be another key contributor
to cellular transformation. The frequency and diverse
patterning of tumor-speciﬁc promoter methylation in our
panel of lung, colon, prostate, and breast carcinomas,
coupled with the ﬁndings recently reported by others,
indicate that tumor-acquired promoter hypermethylation
patterns are nonrandom [6,65]. While it is possible that
random methylation events are ongoing in cancer cells, that
some genes are so frequently methylated across different
tumors but not in adjacent normal tissues suggests to us that
something about their function or primary sequence makes
them particularly susceptible to aberrant promoter hyper-
methylation during cellular transformation.
By contrasting the genome-wide changes in gene expres-
sion of normal and lung cancer cells, we were able to gain
insight into the complexity of the methylation program
required for cells to become fully malignant. Even though we
began with a highly structured, organ-speciﬁc screen, by
applying successive biological and statistical ﬁlters we
identiﬁed several genes with exceptionally high methylation
frequencies and tumor speciﬁcity in primary lung and breast
tumors. Several of these genes also show signiﬁcant methyl-
ation in colon and prostate tumors, but not in counterpart
benign tissues. We conclude that, while tumors differ in their
molecular phenotypes and pathogenesis, the pathways they
follow toward malignancy may be similar and may be
reﬂected in the methylation programs they engage. If true,
it follows that identifying the common pathways tumor cells
use and the methylation proﬁles they impart may be useful to
exploit for early diagnosis or therapeutic intervention.
Supporting Information
Figure S1. Scatter Plots Showing Gene Expression Changes after 5-
Aza Treatment in NSCLC
(A) H157: 2-fold changes show more than 4,000 genes up-regulated,
with similar numbers down-regulated.
(B) H1819: 2-fold changes show fewer than 1,000 genes regulated both
up and down in this cell line.
(C) H460: 4-fold changes.
(D) H1819: 4-fold changes. Red dots indicate up-regulated genes;
green indicates down-regulated genes.
Found at doi:10.1371/journal.pmed.0030486.sg001 (136 KB PDF).
Figure S2. Scatter Plots Showing Gene Expression Changes in HBEC
Cell Lines after 5-Aza Treatment
(A) HBEC2: 2-fold changes.
(B) HBEC3: 2-fold changes.
(C) HBEC4: 2-fold changes.
(D) Average 2-fold changes for all three HBECs
Found at doi:10.1371/journal.pmed.0030486.sg002 (153 KB PDF).
Figure S3. Complete-Linkage Cluster Analysis of 5-Aza-Induced
Genes (before Filtering) in HBEC and NSCLC Cell Lines (U133 Plus
2.0) Used for This Study
Found at doi:10.1371/journal.pmed.0030486.sg003 (9 KB PDF).
Figure S4. Complete-Linkage Cluster Analysis of 5-Aza-Induced
Genes (before Filtering) in HBEC, NSCLC, Breast, SCLC, and Colon
Cancer Cell Lines (U133 Plus 2.0) Used for This Study
Found at doi:10.1371/journal.pmed.0030486.sg004 (10 KB PDF).
Figure S5. Complete-Linkage Cluster Analysis of 5-Aza-Induced
Genes (132-Gene 5-Aza Induction Set) in HBEC and NSCLC Cell
lines (U133 Plus 2.0) Used for This Study
Found at doi:10.1371/journal.pmed.0030486.sg005 (10 KB PDF).
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Figure S6. Comparison of the Gene Expression Proﬁles for the 5-Aza
Induction Gene Set in HBEC, NSCLC, and Breast Cancer Cell Lines
(A) Heat map showing relative gene expression for the 132 5-aza-
induced gene set as well as those that passed all criteria except that
they lacked a CpG island.
(B) Cluster analysis of breast, NSCLC, and HBEC lines using the gene
set from (A).
Found at doi:10.1371/journal.pmed.0030486.sg006 (50 KB PDF).
Figure S7. Histogram of QPCR Data for 5-Aza-Induced Gene
Expression Changes in Breast Cancer Cell Lines
Found at doi:10.1371/journal.pmed.0030486.sg007 (17 KB PDF).
Figure S8. Sodium Bisulﬁte Sequencing Results for BNC1 Promoter
Region in NSCLC Cell Lines Compared to HBECs and Normal PBCs
(Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg008 (14 KB PDF).
Figure S9. Sodium Bisulﬁte Sequencing Results for MSX1 Promoter
Region in NSCLC Cell Lines Compared to HBECs and Normal PBCs
(Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg009 (25 KB PDF)
Figure S10. Sodium Bisulﬁte Sequencing Results for ALDH1A3
Promoter Region in NSCLC Cell Lines Compared to HBECs and
Normal PBCs (Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg010 (20 KB PDF)
Figure S11. Sodium Bisulﬁte Sequencing Results for LOX Promoter
Region in NSCLC Cell Lines Compared to HBECs and Normal PBCs
(Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg011 (19 KB PDF).
Figure S12. Sodium Bisulﬁte Sequencing Results for CTSZ Promoter
Region in NSCLC Cell Lines Compared to HBECs and Normal PBCs
(Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg012 (19 KB PDF).
Figure S13. Sodium Bisulﬁte Sequencing Results for SOX15 Promoter
Region in NSCLC Cell Lines Compared to HBECs and Normal PBCs
(Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg013 (26 KB PDF).
Figure S14. Sodium Bisulﬁte Sequencing Results for CCNA1 Promoter
Region in NSCLC Cell Lines Compared to HBECs and Normal PBCs
(Mixture)
Found at doi:10.1371/journal.pmed.0030486.sg014 (30 KB PDF).
Protocol S1. Primer Sequences and PCR Conditions for MSP
Found at doi:10.1371/journal.pmed.0030486.sd001 (54 KB XLS).
Table S1. Bioinformatic Analysis of 5-Aza-Induced Genes in HBECs
Gene expression in immortalized cells is signiﬁcantly affected by 5-
aza treatment.
Found at doi:10.1371/journal.pmed.0030486.st001 (17 KB XLS).
Table S2. Raw Data for Figure 3
Raw data underlying the heat map in Figure 3.
Found at doi:10.1371/journal.pmed.0030486.st002 (114 KB XLS).
Table S3. SAM Analysis of 5-Aza Gene Set in Primary Tumors
SAM analysis of 5-aza-induction gene set in primary tumors and
companion normal lung.
Found at doi:10.1371/journal.pmed.0030486.st003 (159 KB XLS).
Table S4. Overlapping Gene Set Between the Current Study and a
Previous Study
Comparison between the present study and a previously published
set of microarray experiments using pancreatic cancer cell lines
[41].
Found at doi:10.1371/journal.pmed.0030486.st004 (204 KB XLS).
Table S5. Analysis of Overlap between the Current Study and a
Previous Study
Bioinformatic analysis of overlapping gene set between Sato et al. [41]
and the current study.
Found at doi:10.1371/journal.pmed.0030486.st005 (26 KB XLS).
Accession Numbers
The microarray data for the 5-aza induction experiments
are deposited at the GEO database (http://www.ncbi.nlm.nih.
gov/projects/geo/) under the accession ID GSE5816.
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Editors’ Summary
Background. Tumors or cancers contain cells that have lost many of the
control mechanisms that normally regulate their behavior. Unlike normal
cells, which only divide to repair damaged tissues, cancer cells divide
uncontrollably. They also gain the ability to move round the body and
start metastases in secondary locations. These changes in behavior result
from alterations in their genetic material. For example, mutations
(permanent changes in the sequence of nucleotides in the cell’s DNA) in
genes known as oncogenes stimulate cells to divide constantly.
Mutations in another group of genes—tumor suppressor genes—
disable their ability to restrain cell growth. Key tumor suppressor genes
are often completely lost in cancer cells. But not all the genetic changes
in cancer cells are mutations. Some are ‘‘epigenetic’’ changes—chemical
modifications of genes that affect the amount of protein made from
them. In cancer cells, methyl groups are often added to CG-rich
regions—this is called hypermethylation. These ‘‘CpG islands’’ lie near
gene promoters—sequences that control the transcription of DNA into
RNA, the template for protein production—and their methylation
switches off the promoter. Methylation of the promoter of one copy of
a tumor suppressor gene, which often coincides with the loss of the
other copy of the gene, is thought to be involved in cancer develop-
ment.
Why Was This Study Done? The rules that govern which genes are
hypermethylated during the development of different cancer types are
not known, but it would be useful to identify any DNA methylation
events that occur regularly in common cancers for two reasons. First,
specific DNA methylation markers might be useful for the early detection
of cancer. Second, identifying these epigenetic changes might reveal
cellular pathways that are changed during cancer development and so
identify new therapeutic targets. In this study, the researchers have used
a systematic biological screen to identify genes that are methylated in
many lung, breast, colon, and prostate cancers—all cancers that form in
‘‘epithelial’’ tissues.
What Did the Researchers Do and Find? The researchers used
microarray expression profiling to examine gene expression patterns in
several lung cancer and normal lung cell lines. In this technique, labeled
RNA molecules isolated from cells are applied to a ‘‘chip’’ carrying an
array of gene fragments. Here, they stick to the fragment that represents
the gene from which they were made, which allows the genes that the
cells express to be catalogued. By comparing the expression profiles of
lung cancer cells and normal lung cells before and after treatment with a
chemical that inhibits DNA methylation, the researchers identified genes
that were methylated in the cancer cells—that is, genes that were
expressed in normal cells but not in cancer cells unless methylation was
inhibited. 132 of these genes contained CpG islands. The researchers
examined the promoters of 45 of these genes in lung cancer cells taken
straight from patients and found that 31 of the promoters were
methylated in tumor tissues but not in adjacent normal tissues. Finally,
the researchers looked at promoter methylation of the eight genes most
frequently and specifically methylated in the lung cancer samples in
breast, colon, and prostate cancers. Seven of the genes were frequently
methylated in both lung and breast cancers; four were extensively
methylated in all the tumor types.
What Do These Findings Mean? These results identify several new
genes that are often methylated in four types of epithelial tumor. The
observation that these genes are methylated in multiple independent
tumors strongly suggests, but does not prove, that loss of expression of
the proteins that they encode helps to convert normal cells into cancer
cells. The frequency and diverse patterning of promoter methylation in
different tumor types also indicates that methylation is not a random
event, although what controls the patterns of methylation is not yet
known. The identification of these genes is a step toward building a
promoter hypermethylation profile for the early detection of human
cancer. Furthermore, although tumors in different tissues vary greatly
with respect to gene expression patterns, the similarities seen in this
study in promoter methylation profiles might help to identify new
therapeutic targets common to several cancer types.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030486.
 US National Cancer Institute, information for patients on under-
standing cancer
 CancerQuest, information provided by Emory University about how
cancer develops
 Cancer Research UK, information for patients on cancer biology
 Wikipedia pages on epigenetics (note that Wikipedia is a free online
encyclopedia that anyone can edit)
 The Epigenome Network of Excellence, background information and
latest news about epigenetics
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